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Acute and preventive pharmacological
treatment of post-traumatic headache: a
systematic review
Eigil Lindekilde Larsen1†, Håkan Ashina1†, Afrim Iljazi1, Haidar Muhsen Al-Khazali1, Kristoffer Seem1,
Messoud Ashina1, Sait Ashina2† and Henrik Winther Schytz1*†
Abstract
Background: Post-traumatic headache (PTH) is associated with considerable disability and reduced health-related
quality of life. Despite the very high prevalence of PTH, there are no evidence-based guidelines for PTH treatment.
Thus, we found it timely to provide a systematic review of the current literature on acute and preventive
pharmacological treatment of PTH using PubMed and Embase databases.
Findings: Included studies involved acute and preventive pharmacological treatment of headache attributed to
traumatic injury to the head in adherence to the International Classification of Headache Disorders (ICHD) criteria.
Of 1424 potentially relevant articles identified, 63 were retrieved for detailed evaluation and seven studies (one
prospective and six retrospective) met the inclusion criteria. None of the seven included studies were randomized
clinical trials (RCTs) or used a placebo-controlled study design.
Conclusion: We found that there is a lack of high-quality evidence-based studies on the pharmacological
treatment of PTH. Future studies are highly needed and must emphasize open-label studies with rigorous
methodology or RCTs with a placebo-controlled design.
Keywords: Head injury, Post-traumatic headache, Treatment, Traumatic brain injury, Concussion, Systematic review
Introduction
Post-traumatic headache (PTH) is a common secondary
headache disorder [1] associated with considerable
disability and reduced health-related quality of life [2].
Epidemiological data has shown a lifetime PTH preva-
lence of 4.7% in men and 2.4% in women [3], with
migraine-like and tension-type-like headache being the
most common headache phenotypes [4]. In addition, a
substantial number of PTH patients experience disabling
comorbidities such as symptoms of depression, anxiety,
and sleep disturbances [5].
In the International Classification of Headache Disor-
ders (ICHD) [6], PTH is defined by onset of headache
within seven days following trauma or injury to the head
and/or neck and is also further characterized as either
acute (the first three months from headache onset) or
persistent – the latter being if the headache persists be-
yond 3months.
Despite a very high prevalence of PTH, there are no
evidence-based guidelines for acute or preventive
pharmacological treatment of PTH. The likelihood of
patients receiving optimal treatment is therefore low,
with a high risk of unnecessary treatment exposure. Pa-
tients with very frequent or daily headache following a
trauma are also at risk of developing medication-overuse
headache (MOH) [3].
Current pharmacological treatments for PTH are based
on acute or preventive medications used for primary head-
ache disorders [4, 5], since PTH often mimics a migraine-
like or tension-type headache-like phenotype [6]. This ap-
proach lacks evidence and often results in poor treatment
responses [7]. Furthermore, side effects to pharmacological
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treatment may conflict with PTH comorbidities such as de-
pression and anxiety. Here, we review the current literature
on acute and preventive treatment of PTH and provide a
useful overview for clinicians. In addition, we address meth-
odological limitations and provide recommendations for fu-
ture research.
Methods
Data sources
We searched PubMed and Embase databases for arti-
cles on acute and prophylactic pharmacological PTH
treatment. The search was performed on January 16,
2019 with the following search string: (post traumatic
headache OR post-traumatic headache OR posttrau-
matic headache OR post traumatic migraine OR post-
traumatic migraine OR posttraumatic migraine OR
post concussion headache OR post-concussion head-
ache OR post concussion migraine OR post-concussion
migraine) AND (treatment OR therapy). The search
was performed from database inception until the date
of the database search. The electronic database search
was supplemented with manual searches for pub-
lished, unpublished and ongoing randomized clinical
trials (RCTs) in ClinicalTrials.gov. The search term
was “post-traumatic headache”.
Selection criteria
The search was limited to articles on human subjects
published in English. We also reviewed the reference
lists of relevant primary articles and reviews to iden-
tify studies that were missed in the search process.
All eligible studies were screened in accordance with
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) reporting guidelines.
Study inclusion and data extraction
Inclusion and exclusion criteria are presented in Fig. 1.
We only included studies in which the subjects fulfilled
the diagnostic criteria for headache attributed to trau-
matic injury to the head in accordance with any version
of the International Classification of Headache Disorders
(ICHD) [8]. One investigator (E.L.L) screened all articles
by title and abstract. Following this, two investigators
(E.L.L and A.I.) performed a full-text screening and de-
termined which articles should be included. Another in-
vestigator (H.M.A) subsequently reassessed all the
included articles. Final inclusion was decided by consen-
sus between the three investigators (E.L.L, A. I and
H.M.A). If consensus was not reached, one independent
investigator (H.A) was available to provide advice. For
each study, two investigators (E.L.L and A.I) recorded
data on study design, assessment methods, inclusion
Fig. 1 Eligibility criteria
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criteria, exclusion criteria, age, gender, total number of
subjects, headache phenotype, outcome measures and
other data relevant for the scope of this review.
Results
The database search resulted in a total of 1218 search
hits (Fig. 2). Three additional articles were identified
through a manual search of the reference lists of relevant
primary articles and reviews. A total of 1221 articles
were screened by title and abstract of which 63 articles
were retrieved and assessed for eligibility in the present
study. Seven articles met the inclusion criteria and were
included in the qualitative synthesis [9–15]. Four studies
[9–12] reported on acute PTH treatment, two studies
[13, 14] on preventive PTH treatment and one study
[15] on both acute and preventive PTH treatment. The
studies were very heterogeneous in terms of the study
populations assessed. Thus, three of the seven studies
consisted of pediatric populations [9, 10, 14], one study
was in children or adolescents [12] and one was in a
population with both adults and children [13]. The rest
consisted of a study on military personnel [15], and one
study in an adult population [11]. None of the seven in-
cluded studies were RCTs or included a placebo-
controlled study design. Six studies collected data retro-
spectively [9, 10, 12–15] while one study acquired data
prospectively [11].
Here, we present data focusing first on acute pharma-
cological treatment of PTH and then on preventive
pharmacological treatment of PTH. Table 1 presents
study characteristics for each of the seven included
studies.
Acute pharmacological treatment of post-traumatic
headache
Five studies [9–12, 15] investigated acute pharmacological
PTH treatment. The list of acute medications included
common analgesics such as ketorolac [12], unspecified
non-steroidal anti-inflammatory drugs (NSAIDs) [15],
acetaminophen [15] and combination drugs (Excedrin,
Cafergot and Midrin) [15]. Specific analgesics used were
lidocaine [9, 10], triptans [15] and opioids [15]. Anti-
emetics used were ondansetron [12], metoclopramide [11,
12] and prochlorperazine [12]. Other drugs used were di-
phenhydramine [11], methylprednisolone acetate [9] and
triamcinolone [9].
A retrospective cross-sectional emergency department
(ED) based study investigated the treatment response of
intravenous acute migraine therapies in an adolescent
(aged 8–21 years) group consisting of 254 subjects [12].
All participants presented to the ED within 14 days fol-
lowing mild traumatic brain injury (mTBI). The subjects
received one of the following four intravenous (IV) acute
treatment options: 1) ketorolac only (n = 55), 2) ketoro-
lac and metoclopramide/prochlorperazine (n = 132), 3)
metoclopramide or prochlorperazine (n = 30) and 4)
ondansetron only (n = 37). The dosages used were not
reported. In addition, 95% of the subjects were dis-
charged from the ED and 37% received pre-treatment
with oral analgesics (acetaminophen or ibuprofen) in the
Fig. 2 Flowchart
Larsen et al. The Journal of Headache and Pain           (2019) 20:98 Page 3 of 9
Ta
b
le
1
O
ve
rv
ie
w
of
in
cl
ud
ed
st
ud
ie
s
So
ur
ce
Pa
tie
nt
Po
pu
la
tio
n,
Ba
se
lin
e
St
ud
y
D
es
ig
n
TB
I
Se
ve
rit
y
In
te
rv
en
tio
n
Fo
llo
w
-u
p
El
ig
ib
le
O
ut
co
m
e
M
ea
su
re
s
M
aj
or
Fi
nd
in
gs
C
ha
n
et
al
.
(2
01
5)
[1
2]
25
4
ch
ild
re
n
an
d
ad
ol
es
ce
nt
s,
12
4
M
a ,
13
0
Fa
,m
ea
n
ag
e
13
.8
ye
ar
s
Si
ng
le
-
ce
nt
er
,E
D
,
te
rt
ia
ry
ch
ild
re
n’
s
ho
sp
ita
l,
re
tr
os
pe
ct
iv
e
m
TB
I
A
cu
te
Ph
ar
m
ac
ol
og
ic
al
Tr
ea
tm
en
t.
IV
th
er
ap
ie
s
in
cl
ud
ed
on
e
of
th
e
fo
llo
w
in
g
fo
ur
op
tio
ns
:
-
ke
to
ro
la
c
on
ly
(n
=
55
)
-
ke
to
ro
la
c
an
d
m
et
oc
lo
pr
am
id
e
/
pr
oc
hl
or
pe
ra
zi
ne
(n
=
13
2)
-
m
et
oc
lo
pr
am
id
e
or
pr
oc
hl
or
pe
ra
zi
ne
(n
=
30
)
-
on
da
ns
et
ro
n
on
ly
(n
=
37
)
Th
e
do
sa
ge
s
us
ed
w
er
e
no
t
re
po
rt
ed
.
Th
irt
y-
se
ve
n
pe
rc
en
t
of
th
e
su
bj
ec
ts
w
er
e
pr
et
re
at
ed
w
ith
ei
th
er
ac
et
am
in
op
he
n
or
ib
up
ro
fe
n.
N
on
e
Tr
ea
tm
en
t
su
cc
es
s
de
fin
ed
as
≥
50
%
re
du
ct
io
n
in
pa
in
in
te
ns
ity
as
m
ea
su
re
d
on
a
nu
m
er
ic
ra
tin
g
sc
al
e
fro
m
0
to
10
.
Tr
ea
tm
en
t
su
cc
es
s:
-
Ke
to
ro
la
c
on
ly
:8
0%
-
Ke
to
ro
la
c
pl
us
m
et
oc
lo
pr
am
id
e
or
pr
oc
hl
or
pe
ra
zi
ne
:8
9%
-
M
et
oc
lo
pr
am
id
e
or
pr
oc
hl
or
pe
ra
zi
ne
on
ly
:9
3%
-
O
nd
an
se
tr
on
on
ly
:7
8%
D
ub
ro
vs
ky
et
al
.
(2
01
4)
[1
0]
28
ch
ild
re
n,
6
M
a ,
22
Fa
,
m
ea
n
ag
e
14
.6
ye
ar
s
Si
ng
le
-
ce
nt
er
,
te
rt
ia
ry
re
fe
rr
al
ce
nt
er
,
re
tr
os
pe
ct
iv
e
m
TB
I
A
cu
te
Ph
ar
m
ac
ol
og
ic
al
Tr
ea
tm
en
t.
-
G
O
N
bl
oc
k
(2
%
lid
oc
ai
ne
w
ith
ep
in
ep
hr
in
e)
-
Pe
rip
he
ra
ln
er
ve
bl
oc
ks
of
th
e
le
ss
er
oc
ci
pi
ta
ln
er
ve
an
d
su
pr
ao
rb
ita
ln
er
ve
(o
nl
y
a
su
bg
ro
up
of
pa
tie
nt
s)
Fo
llo
w
-u
p
w
as
co
nd
uc
te
d
us
in
g
a
pa
tie
nt
sa
tis
fa
ct
io
n
su
rv
ey
.
Fi
ve
pa
tie
nt
s
lo
st
to
fo
llo
w
-u
p.
Th
e
ex
ac
t
tim
e
fro
m
in
te
rv
en
tio
n
to
fo
llo
w
-u
p
co
ul
d
no
t
be
ex
tr
ac
te
d
pr
op
er
ly
.
G
oo
d
th
er
ap
eu
tic
ef
fe
ct
de
fin
ed
as
he
ad
ac
he
re
lie
f
la
st
in
g
lo
ng
er
th
an
24
h
or
re
qu
es
te
d
re
pe
at
bl
oc
ks
.
-
93
%
w
ith
go
od
th
er
ap
eu
tic
ef
fe
ct
-
71
%
re
po
rt
ed
co
m
pl
et
e
he
ad
ac
he
re
so
lu
tio
n
im
m
ed
ia
te
ly
fo
llo
w
in
g
th
e
in
te
rv
en
tio
n
-
A
t
th
e
fo
llo
w
-u
p
as
se
ss
m
en
t
(8
2%
fo
llo
w
-u
p
re
sp
on
se
ra
te
),
26
%
of
pa
-
tie
nt
s
re
po
rt
ed
th
at
pe
rip
he
ra
ln
er
ve
bl
oc
ks
ha
d
cu
re
d
th
ei
r
he
ad
ac
he
Er
ic
ks
on
(2
01
1)
[1
5]
10
0
m
ili
ta
ry
pe
rs
on
ne
l,
99
M
a ,
1
Fa
,
m
ea
n
ag
e
28
.7
ye
ar
s
Si
ng
le
-
ce
nt
er
,
cl
in
ic
-b
as
ed
,
re
tr
os
pe
ct
iv
e
m
TB
I
A
cu
te
Ph
ar
m
ac
ol
og
ic
al
Tr
ea
tm
en
t.
-
Tr
ip
ta
ns
(n
=
73
)
-
N
on
-t
rip
ta
ns
(N
SA
ID
s,
ac
et
-
am
in
op
he
n,
op
io
id
s
an
d
co
m
bi
na
tio
n
dr
ug
sb
,n
=
33
)
Th
e
do
sa
ge
s
w
er
e
no
t
re
po
rt
ed
.
N
ot
ab
ly
,2
3%
us
ed
m
or
e
th
an
on
e
ab
or
tiv
e
m
ed
ic
at
io
n.
Pr
ev
en
tiv
e
Ph
ar
m
ac
ol
og
ic
al
Tr
ea
tm
en
t.
O
ne
of
th
e
fo
llo
w
in
g
th
er
ap
ie
s
w
er
e
pr
es
cr
ib
ed
:
-
Tr
ic
yc
lic
an
tid
ep
re
ss
an
ts
(a
m
itr
ip
ty
lin
e
or
no
rt
rip
ty
lin
e,
n
=
48
)
25
–5
0
m
g/
da
y
-
To
pi
ra
m
at
e
10
0
m
g/
da
y
(n
=
29
)
-
Pr
op
ra
no
lo
lL
A
80
m
g/
da
y
(n
=
18
)
-
Va
lp
ro
at
e
ex
te
nd
ed
re
le
as
e
3
m
on
th
s
af
te
r
tr
ea
tm
en
t
st
ar
t,
no
ne
lo
st
to
fo
llo
w
-u
p.
A
t
3
m
on
th
s
po
st
-b
as
el
in
e,
66
of
10
0
su
bj
ec
ts
(3
4%
m
ed
ic
at
io
n
di
sc
on
tin
ua
tio
n
ra
te
)
w
er
e
st
ill
ta
ki
ng
th
e
pr
op
hy
la
ct
ic
tr
ea
t-
m
en
t
th
at
w
as
pr
es
cr
ib
ed
at
ba
se
lin
e.
A
cu
te
Ph
ar
m
ac
ol
og
ic
al
Tr
ea
tm
en
t.
-
H
ea
da
ch
e
re
lie
f
w
ith
in
tw
o
ho
ur
s
af
te
r
in
ta
ke
(n
ot
fu
rt
he
r
sp
ec
ifi
ed
Pr
ev
en
tiv
e
Ph
ar
m
ac
ol
og
ic
al
Tr
ea
tm
en
t.
-
H
ea
da
ch
e
fre
qu
en
cy
de
fin
ed
as
nu
m
be
r
of
da
ys
in
th
e
pr
ev
io
us
m
on
th
w
ith
a
he
ad
ac
he
la
st
in
g
>
30
m
in
-
H
ea
da
ch
e-
re
la
te
d
di
sa
bi
lit
y
as
de
te
r-
m
in
ed
by
M
ID
A
S
A
cu
te
Ph
ar
m
ac
ol
og
ic
al
Tr
ea
tm
en
t.
-
Tr
ip
ta
ns
(n
=
73
an
d
a
70
%
re
sp
on
de
r
ra
te
)
w
er
e
m
or
e
ef
fe
ct
iv
e
co
m
pa
re
d
to
no
n-
tr
ip
ta
ns
(n
=
33
an
d
a
42
%
re
-
sp
on
de
r
ra
te
)
in
te
rm
s
of
he
ad
ac
he
re
lie
f
w
ith
in
tw
o
ho
ur
s
af
te
r
in
ta
ke
(P
=
0.
01
)
Pr
ev
en
tiv
e
Ph
ar
m
ac
ol
og
ic
al
Tr
ea
tm
en
t.
-
Th
e
de
cr
ea
se
in
he
ad
ac
he
fre
qu
en
cy
w
as
si
gn
ifi
ca
nt
fo
r
su
bj
ec
ts
tr
ea
te
d
w
ith
to
pi
ra
m
at
e
(n
=
29
,P
=
0.
02
),
bu
t
no
t
fo
r
an
y
ot
he
r
of
th
e
pr
es
cr
ib
ed
pr
op
hy
la
ct
ic
tr
ea
tm
en
ts
-
57
%
ov
er
al
ld
ec
re
as
e
in
he
ad
ac
he
-
re
la
te
d
di
sa
bi
lit
y
am
on
g
al
ls
ub
je
ct
s
as
m
ea
su
re
d
by
M
ID
A
S
Larsen et al. The Journal of Headache and Pain           (2019) 20:98 Page 4 of 9
Ta
b
le
1
O
ve
rv
ie
w
of
in
cl
ud
ed
st
ud
ie
s
(C
on
tin
ue
d)
So
ur
ce
Pa
tie
nt
Po
pu
la
tio
n,
Ba
se
lin
e
St
ud
y
D
es
ig
n
TB
I
Se
ve
rit
y
In
te
rv
en
tio
n
Fo
llo
w
-u
p
El
ig
ib
le
O
ut
co
m
e
M
ea
su
re
s
M
aj
or
Fi
nd
in
gs
50
0
m
g/
da
y
(n
=
5)
Fr
ie
dm
an
et
al
.
(2
01
8)
[1
1]
21
ad
ul
ts
,5
M
,1
6
F,
m
ea
n
ag
e
45
ye
ar
s
Si
ng
le
-
ce
nt
er
,E
D
,
pr
os
pe
ct
iv
e
N
S
A
cu
te
Ph
ar
m
ac
ol
og
ic
al
Tr
ea
tm
en
t.
IV
m
et
oc
lo
pr
am
id
e
20
m
g
+
de
ph
en
hy
dr
am
in
e
25
m
g.
48
h
+
7
da
ys
,2
pa
tie
nt
s
lo
st
to
fo
llo
w
-u
p.
“S
us
ta
in
ed
he
ad
ac
he
re
lie
f
fo
r
48
h”
,
de
fin
ed
as
m
ild
he
ad
ac
he
or
no
he
ad
ac
he
su
st
ai
ne
d
fo
r
48
h
si
nc
e
ED
di
sc
ha
rg
e
w
ith
ou
t
us
e
of
re
sc
ue
m
ed
ic
at
io
n.
-
A
t
48
h
si
nc
e
ED
di
sc
ha
rg
e,
63
%
re
po
rt
ed
su
st
ai
ne
d
he
ad
ac
he
re
lie
f
fo
r
48
h,
w
hi
le
37
%
co
nt
in
ue
d
to
ex
pe
rie
nc
e
m
od
er
at
e
to
se
ve
re
he
ad
ac
he
s
-
A
t
th
e
1-
w
ee
k
fo
llo
w
-u
p,
53
%
re
-
po
rt
ed
no
or
ra
re
he
ad
ac
he
oc
cu
rr
en
ce
Ku
cz
yn
sk
i
et
al
.
(2
01
3)
[1
4]
44
ch
ild
re
n,
15
M
,2
9
F,
m
ea
n
ag
e
14
.1
ye
ar
s
Si
ng
le
-
ce
nt
er
,
cl
in
ic
-b
as
ed
,
re
tr
os
pe
ct
iv
e
m
TB
I
Pr
ev
en
tiv
e
Ph
ar
m
ac
ol
og
ic
al
Tr
ea
tm
en
t.
Th
e
lis
t
of
pr
op
hy
la
ct
ic
tr
ea
tm
en
ts
us
ed
in
cl
ud
ed
:
-
A
m
itr
ip
ty
lin
e
5
m
g
to
1
m
g/
kg
(n
=
18
)
-
To
pi
ra
m
at
e
12
.5
–2
00
m
g/
da
y
(n
=
6)
a
-M
el
at
on
in
3–
10
m
g/
da
y
(n
=
12
)
-
N
or
tr
ip
ty
lin
e
(n
=
9)
a
an
d
flu
na
riz
in
e
(n
=
8)
a
do
se
s
w
er
e
no
t
sp
ec
ifi
ed
-
17
su
bj
ec
ts
re
ce
iv
ed
m
or
e
th
an
on
e
tr
ea
tm
en
t
i.e
.
ph
ys
ic
al
th
er
ap
y
an
d
bi
of
ee
db
ac
k
th
er
ap
y
Th
e
m
ea
n
fo
llo
w
-u
p
ra
te
w
as
ev
er
y
5.
5
w
ee
ks
un
til
he
ad
ac
he
sy
m
pt
om
s
ha
d
re
so
lv
ed
.N
on
e
lo
st
to
fo
llo
w
-u
p.
Tr
ea
tm
en
t
su
cc
es
s
de
fin
ed
as
≥
50
%
re
du
ct
io
n
in
he
ad
ac
he
fre
qu
en
cy
an
d
w
he
th
er
pr
op
hy
la
ct
ic
tr
ea
tm
en
ts
w
er
e
co
nt
in
ue
d
fo
r
3
m
on
th
s
af
te
r
he
ad
ac
he
re
so
lu
tio
n
an
d
su
bs
eq
ue
nt
ly
gr
ad
ua
lly
di
sc
on
tin
ue
d.
Tr
ea
tm
en
t
su
cc
es
s:
-
A
m
itr
ip
ty
lin
e:
72
%
-
M
el
at
on
in
:7
5%
Se
eg
er
et
al
.
(2
01
5)
[9
]
15
ch
ild
re
n,
5
M
,1
0
F,
m
ea
n
ag
e
15
.5
ye
ar
s
Si
ng
le
-
ce
nt
er
,
cl
in
ic
-b
as
ed
,
re
tr
os
pe
ct
iv
e
m
TB
I
A
cu
te
Ph
ar
m
ac
ol
og
ic
al
Tr
ea
tm
en
t.
A
dm
in
is
tr
at
io
n
of
G
O
N
bl
oc
k
w
as
do
ne
w
ith
2,
5
m
L
2%
lid
oc
ai
ne
(5
0
m
g)
+
0.
5
m
l
m
et
hy
lp
re
dn
is
ol
on
e
ac
et
at
e
(2
0
m
g)
or
2.
5
m
l
tr
ia
m
ci
no
lo
ne
(2
5
m
g)
.
Fo
llo
w
-u
p
as
se
ss
m
en
t
w
as
co
nd
uc
te
d
at
a
m
ea
n
of
5.
6
m
on
th
s
af
te
r
tr
ea
tm
en
t
st
ar
t,
1
pa
tie
nt
lo
st
to
fo
llo
w
-u
p.
Fu
ll
tr
ea
tm
en
t
re
sp
on
se
de
fin
ed
as
≥
50
%
re
du
ct
io
n
in
he
ad
ac
he
fre
qu
en
cy
.
Fu
ll
tr
ea
tm
en
t
re
sp
on
se
:
-
64
%
(9
of
14
pa
tie
nt
s)
-
M
ea
n
he
ad
ac
he
fre
qu
en
cy
w
as
re
du
ce
d
fro
m
26
da
ys
pe
r
m
on
th
to
18
da
ys
pe
r
m
on
th
C
us
hm
an
et
al
.
(2
01
9)
[1
3]
27
7
ch
ild
re
n
an
d
ad
ul
ts
,
13
9
M
a ,
13
8
Fa
,m
ea
n
ag
e
23
.0
ye
ar
sa
Si
ng
le
-
ce
nt
er
,
ac
ad
em
ic
sp
or
ts
m
ed
ic
in
e
pr
ac
tic
e,
re
tr
os
pe
ct
iv
e
m
TB
I
Pr
ev
en
tiv
e
Ph
ar
m
ac
ol
og
ic
al
Tr
ea
tm
en
t.
Pa
tie
nt
s
w
er
e
cl
as
si
fie
d
in
to
th
re
e
gr
ou
ps
:
-
N
o
m
ed
ic
at
io
n
(n
=
12
3)
-
A
m
itr
ip
ty
lin
e
(m
ed
ia
n
do
se
:
20
m
g,
n
=
94
)
-
G
ab
ap
en
tin
(m
ed
ia
n
do
se
:
90
0
m
g,
n
=
60
)
Fo
llo
w
-u
p
da
ta
w
as
co
lle
ct
ed
ov
er
1
ye
ar
af
te
r
tr
ea
tm
en
t
st
ar
t.
St
ud
y
in
cl
us
io
n
w
as
de
pe
nd
en
t
on
at
le
as
t
on
e
fo
llo
w
-u
p
as
se
ss
m
en
t.
Se
lf-
re
po
rt
ed
he
ad
ac
he
sc
or
e,
ra
ng
in
g
fro
m
0
to
6
(0
=
no
sy
m
pt
om
s,
5–
6
=
se
ve
re
sy
m
pt
om
s)
.
-
In
bo
th
m
ed
ic
at
io
n
gr
ou
ps
(g
ab
ap
en
tin
an
d
am
itr
ip
ty
lin
e)
,
he
ad
ac
he
sc
or
es
im
pr
ov
ed
ov
er
tim
e
-
H
ow
ev
er
,h
ea
da
ch
e
sc
or
es
im
pr
ov
ed
si
m
ila
rly
in
th
e
no
m
ed
ic
at
io
n
gr
ou
p
M
m
al
es
,F
fe
m
al
es
,m
TB
Im
ild
tr
au
m
at
ic
br
ai
n
in
ju
ry
,N
S
no
t
sp
ec
ifi
ed
,E
D
em
er
ge
nc
y
de
pa
rt
m
en
t,
PT
H
po
st
-t
ra
um
at
ic
he
ad
ac
he
,I
V
in
tr
av
en
ou
s,
G
O
N
gr
ea
te
r
oc
ci
pi
ta
ln
er
ve
,N
SA
ID
s
no
ns
te
ro
id
al
an
ti-
in
fla
m
m
at
or
y
dr
ug
s
a D
at
a
ha
s
be
en
ca
lc
ul
at
ed
ba
se
d
on
da
ta
pr
ov
id
ed
in
th
e
st
ud
ie
s
b
In
cl
ud
es
Ex
ce
dr
in
,C
af
er
go
t,
an
d
M
id
rin
Larsen et al. The Journal of Headache and Pain           (2019) 20:98 Page 5 of 9
ED. The primary outcome was ≥50% reduction in head-
ache intensity score during the ED visit as measured on
a numeric rating scale (NRS) from 0 to 10. The overall
treatment response was 87% with approximately half of
the subjects reporting complete resolution of headache.
The treatment response of each of the four drug combi-
nations is described in Table 1.
In a retrospective case series study, 28 children with
PTH (aged 10–17 years) reported tenderness over the
greater occipital nerve (GON) following palpation [10].
The patients were then treated with peripheral nerve
blocks of the scalp, including GON blocks, lesser occipi-
tal nerve blocks and supraorbital nerve blocks. The
blocks contained 2% lidocaine with epinephrine. The
primary outcome was to examine the proportion of pa-
tients with good effect (pain relief > 24 h and/or repeat
blocks requested), partial effect (pain relief < 24 h and no
subsequent request for repeat blocks) or no effect (poor
or no pain relief following intervention). Pain relief was
defined as < 3/10 pain intensity on a NRS from 0 to 10.
The first peripheral nerve blocks were conducted at a
mean of 70 days since the mTBI. Fifty-seven percent of
the subjects had a history of multiple concussions, while
70% had a history of headache prior to the mTBI.
Ninety-three percent of the subjects reported good
therapeutic effect, while the rest reported partial effect.
In addition, 71% of the subjects reported complete head-
ache resolution following the intervention. A patient sat-
isfaction survey was conducted post-intervention (82%
follow-up response rate) with 26% of subjects reporting
that peripheral nerve blocks had cured their headache.
The time interval from treatment start to survey re-
sponse was not further specified. Moreover, the authors
reported that 82% received intravenous metoclopramide
treatment prior to the first treatment with peripheral
nerve blocks. Following metoclopramide treatment, 32%
of subjects reported complete immediate headache reso-
lution while 44% achieved partial and 24% no headache
relief, respectively. Intravenous metoclopramide treat-
ment was conducted at a mean of 39 days since the
mTBI. The authors did not report the dosages used for
intravenous metoclopramide treatment.
In another case series, Seeger et al. [9] performed a
retrospective chart review in 15 children (mean age: 15;
range 13–17) with PTH attributed to mTBI, who were
treated with GON blocks. Follow-up data was obtained
from 14 of 15 subjects at 6 months after the interven-
tion. The time range from injury to intervention was 1–
12months with 11 subjects reporting persistent PTH
(duration > 3months). The primary outcome was “full
response” defined as ≥50% reduction in headache fre-
quency or “partial response” defined as reduction in
headache frequency less than 50%. Sixty-four percent of
the subjects reported “full response” at the follow-up
assessment, while one subject reported “partial re-
sponse”. Mean headache frequency was reduced from
26 ± 7 days per month pre-mTBI to 18 ± 12 days per
month post-mTBI (P = 0.014).
A prospective ED-based open-label study investigated
headache relief in 21 patients treated with intravenous
metoclopramide 20 mg and diphenhydramine 25 mg
after acute PTH attributed to TBI [11]. All patients re-
ported TBI within the past 10 days at the time of inter-
vention, and 90% provided data at both the 48 h and
one-week follow-up. The primary outcome was “sus-
tained headache relief for 48 h”, defined as mild head-
ache or no sustained headache for 48 h since ED
discharge without use of rescue medication. At 48 h
since ED discharge, 63% reported sustained headache re-
lief for 48 h, while 37% continued to experience moder-
ate to severe headaches. At the one-week follow-up, 53%
reported no or rare headache occurrence.
An observational retrospective cohort single-center
study at a US Army neurology clinic investigated treat-
ment outcomes in 100 military personnel with de novo
PTH attributed to mTBI [15]. Seventy-seven percent of
the subjects had sustained a blast-related mTBI, while
23% had suffered a non-blast mTBI. In addition, 52%
screened positive for post-traumatic stress disorder,
while 38% screened positive for depression. More than
90% of the subjects presented with a migraine-like head-
ache. The mean time since PTH-onset was 18months,
and the mean headache frequency was 17 days per
month. This study mainly focused on preventive PTH
treatment but did also provide data on acute PTH treat-
ment. The author reported that triptans (n = 73 and a
70% responder rate) were more effective compared to
non-triptans (n = 33 and a 42% responder rate) in terms
of headache relief (not further specified) within two
hours after intake (P = 0.01). Notably, 23% used more
than one abortive medication.
Preventive pharmacological treatment of post-traumatic
headache
Three studies investigated preventive pharmacological
PTH treatment. One study included military personnel
[15], one study included a pediatric sample [14] and one
study included a combined adult and pediatric popula-
tion [13]. The list of preventive medications used in-
cluded: amitriptyline [13–15], nortriptyline [14, 15],
topiramate [14, 15], propranolol [15], valproate [15],
melatonin [14], gabapentin [13] and flunarizine [14].
In the aforementioned military study [15], 100 subjects
received the following prophylactic medications: tricyclic
antidepressants (amitriptyline or nortriptyline, n = 48)
25–50mg/day, topiramate (n = 29) 100 mg/day, propran-
olol (n = 18) 80 mg/day and valproate (n = 5) 500 mg/
day). Some patients also received non-pharmacological
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treatment (e.g. physical therapy, neuropsychology) dur-
ing the observational period. Subjects were allowed to
use abortive medication such as NSAIDs (n = 18) and
triptans (n = 73). Primary outcome measures were
assessed by phone three months after baseline evaluation
and included: 1) number of days in the previous month
with a headache lasting more than 30 min, 2) headache-
related disability as determined by Migraine Disability
Assessment (MIDAS) questionnaire, and 3) whether
headaches were reliably relieved within 2 h after intake
of abortive medication. This study found that headache
frequency decreases with 2.6 days (− 15.5%, P = 0.009) at
follow-up compared to baseline after the subjects started
on prophylactic treatment. Thirty-five percent experi-
enced a ≥ 50% decrease in headache frequency. The de-
crease in headache frequency was significant for subjects
treated with topiramate (n = 29, P = 0.02), but not for
any of the other prescribed prophylactic treatments. At
three months post-baseline, 66 of 100 subjects (34%
medication discontinuation rate) were still taking the
prophylactic treatment that was prescribed at baseline.
Moreover, the study found a 57% decrease in headache-
related disability among all subjects as measured by
MIDAS. In conclusion, the authors stated that topira-
mate could be an effective prophylactic drug for PTH,
while triptans appeared to be the most efficient abortive
medication for PTH. However, these findings would
need to be validated in prospective, placebo-controlled
RCTs.
Kuczynski et al. [14] investigated the efficacy of
prophylactic PTH treatment using a retrospective chart
review in 44 children (mean age: 14), who attended a
brain injury clinic due to PTH. The mean time since
traumatic brain injury (TBI) was 7 months (range: 1–29
months) and 61% reported daily headaches. The list of
prophylactic treatments used in the study included: ami-
triptyline (5 mg/day to 1 mg/kg/day), nortriptyline (dos-
age not specified), topiramate (12.5 to 200mg/day),
melatonin (3–10mg/day) and flunarizine (dosage not
specified). The primary outcome was a ≥ 50% reduction
in headache frequency and whether prophylactic treat-
ments were continued for 3 months after headache reso-
lution and subsequently gradually discontinued. The
authors reported that the overall treatment response was
64%. More specifically, melatonin and amitriptyline
yielded a treatment success rate of 75% (9 of 12 subjects)
and 72% (13 of 18 subjects), respectively. However, 39%
received more than one treatment i.e. physical therapy
and biofeedback therapy.
A retrospective cohort study in an academic sports
medicine practice classified patients into three groups:
gabapentin group (median dose: 900 mg, n = 60), ami-
triptyline group (median dose: 20 mg, n = 94) and no
medication group (n = 123) [13]. The latter was defined
as subjects who had not been prescribed any pharmaco-
logical treatment during the study period. No patient
was prescribed both gabapentin and amitriptyline. A 7-
point numeric rating scale from 0 to 6 (0 no headache,
5–6 severe headache) was used to record headache
scores. In the gabapentin and amitriptyline groups, most
subjects (~ 80%) were prescribed pharmacological treat-
ment at the first or second visits (median time since
mTBI: 4.3 weeks) and inclusion was based on at least
one follow-up visit after treatment initiation. Therefore,
146 subjects were excluded because they did not have
follow-up measurements. The reasons for loss to follow-
up were not available. For the 277 PTH patients that
were included in the final analysis, the mean number of
physician visits per patient was 4.1 during a mean period
of 4.8 months. In both medication groups (gabapentin
and amitriptyline), headache scores improved over time.
However, headache scores improved similarly in the no
medication group.
Discussion
In conclusion, we found a lack of quality studies on both
acute and preventive pharmacological treatment of PTH.
Based on data reviewed from seven studies, efficacy of
any pharmacological intervention could not be inferred
as discussed below. The included studies used an open-
label design limited by both investigator-subject inter-
action and placebo response. The latter varies widely
across clinical trials with both acute and preventive med-
ications for migraine [16–18]. A similar placebo effect
could be expected in PTH patients. The primary and
secondary endpoints varied between the included stud-
ies, making treatment comparisons unfeasible. In
addition, 5 of 7 included studies included pediatric pop-
ulations. In this context, it is worth noting that high pla-
cebo responses to pharmacological treatment have
previously been reported in pediatric migraine patients
[19]. Furthermore, the studies were also considerably
underpowered with sample sizes ranging from 15 to 277
patients. In addition, the only prospective study included
did not even establish baseline headache characteristics
using a prospectively collected headache diary [11].
Some of the reviewed studies included subjects with sub-
stantial within-study variance in terms of time range
from TBI to intervention [9, 10, 13–15]. As an example,
the preventive treatment study [14] included 44 children
with a mean time period since TBI of 7 months (range:
1–29 months). Thus, it is highly likely that some of the
subjects experienced spontaneous reduction in headache
frequency during the treatment period.
Recommendations for future research
Further research in acute and preventive treatment for
PTH is highly warranted. Data analysis can be greatly
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enhanced, if consensus guidelines for controlled trials of
acute and preventive treatment of PTH are provided.
We suggest several aspects that should be considered to
improve data consistency and study design reliability.
First, future RCTs should include a double-blinded, ran-
domized, parallel-group study design. This would enable
us to prove drug efficacy and provide robust information
on safety and tolerability. Second, future open-label stud-
ies and RCTs should require included subjects to fulfill
the ICHD criteria for PTH to reduce population hetero-
geneity. A future version of the ICHD may benefit from
subdividing PTH based on headache phenotype, as there
could be differences in treatment outcome depending on
the headache phenotype. Along this line of reasoning,
detailed characterization of initial injury severity and
type (i.e. GCS or computer tomography/magnetic reson-
ance imaging classification) would also offer much
needed patient stratification, which in turn could pro-
vide more targeted treatment approaches for individual
patients. Third, baseline data on headache characteristics
(including headache phenotype), headache ‘triggers’ (i.e.
physical and cognitive activity), comorbid psychiatric ill-
ness (e.g. anxiety and depression), number of TBIs, pre-
trauma history of headache and other relevant data
should be recorded prior to intervention. Fourth, pri-
mary and secondary endpoints should be similar among
future studies. In this context, the International Head-
ache Society (IHS) has provided guidelines for controlled
trials of acute and preventive treatment of migraine [20,
21]. These guidelines could serve as inspiration, which
would enable us to compare efficacy of acute and pre-
ventive migraine drugs between PTH and migraine pa-
tients. Lastly, PTH patients often present with a plethora
of symptoms (i.e. fatigue, depression, sleep disturbances)
and not only headache [2, 22]. It would be interesting if
future RCTs and high-quality open-label studies in-
cluded secondary endpoints set to investigate drug effi-
cacy on factors such as health-related quality of life,
work productivity and levels of anxiety and depression.
Conclusion
This systematic review has shown a low level of evidence
to support any pharmacological treatment of PTH.
High-quality RCTs and open-label studies are needed to
provide robust evidence of clinical utility. Future re-
search efforts should be driven by rigorous methodology
and improved outcome assessment of analytical validity.
In addition, PTH patients display a myriad of comorbid
symptoms (i.e. depression, anxiety, sleep disturbances).
Thus, future studies should include multidimensional
outcome scales that cover multiple symptom domains.
This will facilitate more targeted treatment approaches
that accounts for clinical variability between patients
and better reflects the concept of precision medicine.
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